Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Illumina, Inc

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Sci. Aging Knowl. Environ., 17 September 2003
Vol. 2003, Issue 37, p. or16

OTHER RESOURCES

Transcriptional Repression of Atherogenic Inflammation: Modulation by PPAR{delta}

Chih-Hao Lee, Ajay Chawla, Ned Urbiztondo, Debbie Liao, William A. Boisvert, and Ronald M. Evans

http://sageke.sciencemag.org/cgi/content/abstract/sageke;2003/37/or16

Abstract: Science 11 September 2003 (10.1126/science.1087344) (Science Express Reports)

The formation of an atherosclerotic lesion is mediated by lipid-laden macrophages (foam cells), which also establish chronic inflammation associated with lesion progression. The peroxisome proliferator-activated receptor (PPAR) {gamma} promotes lipid uptake and efflux in these atherogenic cells. In contrast, we found that the closely related receptor PPAR{delta} controls the inflammatory status of the macrophage. Deletion of PPAR{delta} from foam cells increased the availability of inflammatory suppressors, which in turn reduced atherosclerotic lesion by more than 50%. We propose an unconventional ligand-dependent transcriptional pathway in which PPAR{delta} controls an inflammatory switch through its association and disassociation with transcriptional repressors. PPAR{delta} and its ligands may thus serve as therapeutic targets to attenuate inflammation and slow the progression of atherosclerosis.

Abstract/PDF

ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products